This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients [6 subjects for Lead-in and 24 for Phase 2] enrolled with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with GEM-NAB-P (GEM 1000mg/m2 IV and NAB-P 125 mg/m2 given days 1, 8, and 15 every 28 days, and proglumide will be tested at the daily dose of 1200 mg orally given as 400 mg po TID. The lead-in study will determine the safety and tolerability of the 1200 mg daily dose of proglumide with standard of care GEM-NAB-P. If 0 or 1 of a total of 6 patients at 400mg experiences a DLT, then we will proceed to the Phase 2 randomized trial.

Start Date31 Jan 2024

Sponsor / Collaborator

Georgetown University

NCT05551858 / Active, not recruitingPhase 1/2IIT

A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months

Chronic pancreatitis is a rare but debilitating condition associated with chronic abdominal pain, diarrhea, diabetes, and an 8-fold increased risk for the development of pancreatic cancer. Unfortunately, there is no available treatment to prevent the progression of chronic pancreatitis, and most subjects require narcotic medications to control the pain. A receptor protein call the CCK-B receptor becomes activated in chronic pancreatitis and is in part responsible for the scar tissue or fibrosis that occurs and responsible for the cancer risk. In mice with chronic pancreatitis, the inflammation and damage was reversed with an old drug called proglumide that blocks the activation of the CCK-B receptor. Proglumide has also been shown to possibly reduce pain.
This protocol involved a 2-Part study to test the safety of oral proglumide in those with confirmed chronic pancreatitis and the second goal is to determine if proglumide improves pain and function of the pancreas. Part-1 is an open-labelled Lead-in Study of N=8 subjects over a 12-week treatment period. Part-2 is a randomized double blind pseudo cross over study where subjects will be treated in Arm A (placebo for 12 weeks followed by 12 weeks of proglumide) and Arm B ( proglumide for 24 weeks).

Start Date17 Nov 2022

Sponsor / Collaborator

Georgetown University

NCT04814602 / CompletedEarly Phase 1IIT

Single-dose Pharmacokinetic (PK) Assessment of Oral Proglumide in Those With Hepatic Impairment

Proglumide is an oral cholecystokinin (CCK) receptor antagonist that has been shown in non-clinical studies to reverse hepatic fibrosis and decrease the incidence of hepatocellular carcinoma (HCC). Because of these potential beneficial properties, proglumide may be useful in decreasing the fibrosis and risk for HCC in those with cirrhosis. Although proglumide is safe in those with normal hepatic function, the pharmacokinetics have not been established in those that are hepatic impaired. The purpose of this study is to analyze proglumide blood levels and excretion in subjects with cirrhosis compared to health controls.

Start Date30 Mar 2021

Sponsor / Collaborator

Georgetown University

100 Clinical Results associated with Proglumide

100 Translational Medicine associated with Proglumide

100 Patents (Medical) associated with Proglumide

505

Literatures (Medical) associated with Proglumide

01 Mar 2024·3 Biotech

Molecular authentication, metabolite profiling and in silico–in vitro cytotoxicity screening of endophytic Penicillium ramusculum from Withania somnifera for breast cancer therapeutics

Article

Author: Haldar, Niladri ; Rajeshkumar, K C ; Shaikh, Aazam ; Jisha, M S ; Varghese, Sherin ; Gajbhiye, Virendra

In the present study, we isolated a potent endophytic fungus from the roots of Withania somnifera. The endophytic fungal strain was authenticated as Penicillium ramusculum SVWS3 based on morphological and molecular sequencing using four gene data and phylogenetic analyses. In vitro cytotoxicity studies unveiled the remarkable cytotoxic potential of the crude extract derived from P. ramusculum, exhibiting dose-dependent effects on MDA-MB-468 and MCF-7 cells. At a concentration of 100 µg/mL, the crude extract resulted in cell viability of 29.78% for MDA-MB-468 cells and 14.61% for MCF-7 cells. The IC₅₀ values were calculated as 62.83 ± 0.93 µg/mL and 17.23 ± 1.43 µg/mL, respectively for MDA-MB-468 and MCF-7 cells. Caspase activation assay established the underlying mechanism of the crude extract depicting the activation of caspases 3 and 7, indicating the induction of apoptosis in MCF-7 cells. Chemotaxonomic profiling elucidated the ability of P. ramusculum to synthesize a diverse array of bioactive compounds, including Fasoracetam, Tryprostatin B, Odorinol, Thyronine, Brevianamide F, Proglumide, Perlolyrine, Tyrphostin B48, Baptifoline, etc. Molecular docking studies inferred that Baptifoline, Brevianamide F, Odorinol, Perlolyrine, Thyronine, Tryphostin B48, and Tryprostatin B were the lead compounds that could effectively interact with the five selected target receptors of breast cancer, further surpassing the positive controls analyzed. Pharmacokinetic profiling revealed that Baptifoline, Odorinol, and Thyronine depicted an excellent therapeutic profile of druggability. These findings collectively substantiate the anticancer activity of bioactive metabolites synthesized by P. ramusculum SVWS3. Hence, the endophytic P. ramusculum SVWS3 can be an authentic source for developing novel chemotherapeutic drug formulations.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13205-023-03906-3.

01 Mar 2024·American Journal of Physiology-Gastrointestinal and Liver Physiology

Implicating the cholecystokinin B receptor in liver stem cell oncogenesis

Article

Author: Yassin, Amal A ; Huang, Yimeng ; Smith, Jill P ; Fang, Hongbin ; Shivapurkar, Narayan ; Drda, Jack C ; Duka, Tetyana ; Chen, Wenqiang ; Gay, Martha D

This investigation identified a novel pathway involving the activation of hepatic stem cells and liver oncogenesis. Receptor blockade or genetic disruption of the cholecystokinin-B receptor (CCK-BR) signaling pathway decreased the activation and proliferation of hepatic stem cells after liver injury without eliminating the regenerative capacity of healthy hepatocytes.

18 May 2023·Cancers

Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic.

Article

Author: Shivapurkar, Narayan ; Cheema, Amrita ; Bansal, Sunil ; Chen, Wenqiang ; Jolly, Gurbani ; Smith, Jill P ; Duka, Tetyana

CCK receptors are expressed on pancreatic cancer epithelial cells, and blockade with receptor antagonists decreases tumor growth. Activated pancreatic stellate cells or myofibroblasts have also been described to express CCK receptors, but the contribution of this novel pathway in fibrosis of the pancreatic cancer microenvironment has not been studied. We examined the effects of the nonselective CCK receptor antagonist proglumide on the activation, proliferation, collagen deposition, differential expression of genes, and migration in both murine and human PSCs. CCK receptor expression was examined using western blot analysis. Collagen production using activated PSCs was analyzed by mass spectroscopy and western blot. Migration of activated PSCs was prevented in vitro by proglumide and the CCK-B receptor antagonist, L365,260, but not by the CCK-A receptor antagonist L365,718. Proglumide effectively decreased the expression of extracellular matrix-associated genes and collagen-associated proteins in both mouse and human PSCs. Components of fibrosis, including hydroxyproline and proline levels, were significantly reduced in PSC treated with proglumide compared to controls. CCK peptide stimulated mouse and human PSC proliferation, and this effect was blocked by proglumide. These investigations demonstrate that targeting the CCK-B receptor signaling pathway with proglumide may alter the plasticity of PSC, rendering them more quiescent and leading to a decrease in fibrosis in the pancreatic cancer microenvironment.

News (Medical) associated with Proglumide

19 Oct 2017

·www.bioportfolio.com

Global Proglumide Market Research Report Forecast 20172022 [Report Updated: 18092017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed. The Global Proglumide Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Proglumide industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Proglumide market study provides comprehensive data which enhances the understanding, scope and application of this report. This report provides comprehensive analysis of Key market segments and subsegments Evolving market trends and dynamics Changing supply and demand scenarios Quantifying market opportunities through market sizing and market forecasting Tracking current trends/opportunities/challenges Competitive insights Opportunity mapping in terms of technological breakthroughs Global Proglumide Market: Regional Segment Analysis North America Europe China Japan Southeast Asia India The Major players reported in the market include: Tianyuan Pharmachemical Institute Hubei Prosoerity Galaxy Chemical Hubei Yikangyuan Chemical Hubei Yuancheng Saichuang Technology company 5 company 6 company 7 company 8 company 9 ... Global Proglumide Market: Product Segment Analysis Type 1 Type 2 Type 3 Global Proglumide Market: Application Segment Analysis Application 1 Application 2 Application 3 Reasons for Buying this Report This report provides pinpoint analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth It provides a sixyear forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making indepth analysis of market segments

100 Deals associated with Proglumide

External Link

KEGG	Wiki	ATC	Drug Bank
D01818	Proglumide	A02BX06	DB13431

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Peptic Ulcer	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatitis, Chronic	Preclinical	US	CCKr Therapeutics, Inc.	01 Jul 2024
Hepatocellular Carcinoma	Preclinical	US	CCKr Therapeutics, Inc.	13 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis